Evidence map›Paper›PMID 38069363›Full record

ArticleInternational journal of molecular sciences2023

Dual Effects of 3-

Yung-Ju Yeh, Tai-Ling Chao, Yu-Jen Chang, Sui-Yuan Chang, Chih-Hao Lu, Chih-Hua Chao, Wen-Chi Su, Ching-Ping Tseng, Michael M C Lai, Ju-Chien Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Yung-Ju YehDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404328, Taiwan.ORCID 0000-0001-8263-1532
Tai-Ling ChaoDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei 100229, Taiwan.
Yu-Jen ChangThe Ph.D. Program of Biotechnology and Biomedical Industry, China Medical University, Taichung 404328, Taiwan.
Sui-Yuan ChangDepartment of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei 100229, Taiwan.
Chih-Hao LuInstitute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, Hsinchu 300093, Taiwan.
Chih-Hua ChaoSchool of Pharmacy, China Medical University, Taichung 4060404, Taiwan.ORCID 0000-0002-1410-3516
Wen-Chi SuResearch Center for Emerging Viruses, China Medical University Hospital, Taichung 404328, Taiwan.
Ching-Ping TsengDepartment of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan 33302, Taiwan.ORCID 0000-0002-2587-210X
Michael M C LaiResearch Center for Emerging Viruses, China Medical University Hospital, Taichung 404328, Taiwan.
Ju-Chien ChengDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung 404328, Taiwan.
China Medical University · TWNational Taiwan University · TWChang Gung University · TWNational Yang Ming Chiao Tung University · TW

Funding

Chang Gung Medical Foundation(Taiwan) CORPD1K0031, CMRPD1L0281-2, and CMRPD1N0211-3China Medical University(Taiwan) CMU110-S-42, CMU110-MF-37, CMU111-S-39National Science and Technology Council(Taiwam) 110-2320-B-039-054-MY3
6 · The paper itself

Abstract

The continuous emergence of SARS-CoV-2 variants has led to a protracted global COVID-19 pandemic with significant impacts on public health and global economy. While there are currently available SARS-CoV-2 vaccines and therapeutics, most of the FDA-approved antiviral agents directly target viral proteins. However, inflammation is the initial immune pathogenesis induced by SARS-CoV-2 infection, there is still a need to find additional agents that can control the virus in the early stages of infection to alleviate disease progression for the next pandemic. Here, we find that both the spike protein and its receptor CD147 are crucial for inducing inflammation by SARS-CoV-2 in THP-1 monocytic cells. Moreover, we find that 3-

Indexed as

COVID-19DaphniphyllumAntiviral AgentsBetulinic AcidCOVID-19 VaccinesHumansInflammationPandemicsSARS-CoV-2Spike Glycoprotein, CoronavirusVirus InternalizationAntiviral AgentsbetulinBetulinic AcidCOVID-19 VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-23-epi-betulininflammationSARS-CoV-2virus entry inhibitor

Identifiers

PMID38069363
PMCPMC10707724
OpenAlexW4389223573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.